Canadian MS Progression Cohort: Administrative Data Analysis

Project number: 
19-049
Approval date: 
Monday, March 2, 2020
Principal Investigator: 
Lynd,Larry
Institution: 
University of British Columbia (UBC)
Funding Agency: 
Multiple Sclerosis Society of Canada,Multiple Sclerosis Society of Canada
Datasets requested: 
PharmaNet
WorkSafeBC
Hospital Separations (BC Ministry of Health)
Consolidation registry (Ministry of Health)
NACRS
Income band (Statistics Canada)
Medical Services Plan (BC Ministry of Health)
Consolidation - demographic (Ministry of Health)
Citizenship and Immigration Canada (CIC) Permanent Residents
Deaths (BC Vital Statistics Agency)
consolidation - census geocodes
Research objective: 

a)Research Questions

Which patient factors (age, concurrent medications, education, socio-economic status, employment, family support), disease (duration, subtype), treatment (lack of DMT, lack of exposure to high-efficacy DMT, delayed start of DMT), and health systems factors (public/private drug coverage, distance from MS clinic, access to multi-disciplinary resources, access to community support groups) associated with the
de novo onset of disease progression in MS?

Which patient, disease, treatment, and health systems factors (as listed above) are affecting the rate of progression in MS?

What is the health economic impact (i.e. quality of life/health utility, health care resource utilization, productivity loss) of disease progression (de novo onset and rate) and how the magnitude of the burden differs by patient characteristics?

b) Hypothesis:
We hypothesize that certain patient characteristics such as age, concurrent medications, disease, and treatment (lack of DMT, lack of exposure to high-efficacy DMT, delayed start of DMT), are associated with the de novo onset and rate of disease progression in MS. Understanding these factors may help predict patient outcomes.


Page last revised: May 5, 2020